In this episode, Rich chats with Dr Conleth Murphy, a consultant medical oncologist and Sue Glavin, Nurse Manager who are both leading the way in scalp cooling treatment at Bon Secours Hospital in Cork, Ireland.
They discuss how patient advocacy played a huge part in integrating scalp cooling into their side effect management practice. As well as the psychosocial impact that scalp cooling can have on patients. Both go into depth about how providing care can limit the impact of cancer on a patient both during and after their treatment.
3:20 – The demand for scalp cooling with patients
4.10 – Why Dr Conleth Murphy went into Oncology
6.23 – Why Sue Glavin went into Oncology
7.50 – Most people have been touched by cancer. How does this effect the care we give?
11.15 – Research from the patient’s perspective
12.34 – The efficacy of scalp cooling
16.02 – Encouraging patients to research scalp cooling before their treatment
18.04 – The difference between patient and doctor efficacy
21.10 – Patients’ reasons for wanting to scalp cool
25.55 – Scalp cooling with anthracyclines
29.47 – The psychosocial impact of scalp cooling
35.51 – Debunking scalp cooling myths
38.45 – What does changing the face of cancer mean to Dr Conleth Murphy & Sue Glavin?
Dr Conleth Murphy, Consultant Oncologist, Bon Secours Hospital in Cork, Ireland Dr. Conleth Murphy (bonsecours.ie)
Sue Glavin, Nurse Manager, Bon Secours Hospital in Cork, Ireland
The uptake, patient satisfaction and efficacy of scalp cooling among patients receiving chemotherapy in an Irish oncology day ward. (2019, Maher et al.) https://www.annalsofoncology.org/article/S0923-7534(19)59968-9/fulltext
Scalp cooling for hair loss prevention in female Japanese breast cancer patients receiving (neo)adjuvant chemotherapy. (2021, Ohsumi et al.) https://scalpcoolingstudies.com/study-library/ohsumi-2020-observational-study/
In this episode, Rich chats with Dr Conleth Murphy, a consultant medical oncologist and Sue Glavin, Nurse Manager who are both leading the way in scalp cooling treatment at Bon Secours Hospital in Cork, Ireland.
They discuss how patient advocacy played a huge part in integrating scalp cooling into their side effect management practice. As well as the psychosocial impact that scalp cooling can have on patients. Both go into depth about how providing care can limit the impact of cancer on a patient both during and after their treatment.
In this episode, Rich chats with Dr Conleth Murphy, a consultant medical oncologist and Sue Glavin, Nurse Manager who are both leading the way in scalp cooling treatment at Bon Secours Hospital in Cork, Ireland.
They discuss how patient advocacy played a huge part in integrating scalp cooling into their side effect management practice. As well as the psychosocial impact that scalp cooling can have on patients. Both go into depth about how providing care can limit the impact of cancer on a patient both during and after their treatment.
3:20 – The demand for scalp cooling with patients
4.10 – Why Dr Conleth Murphy went into Oncology
6.23 – Why Sue Glavin went into Oncology
7.50 – Most people have been touched by cancer. How does this effect the care we give?
11.15 – Research from the patient’s perspective
12.34 – The efficacy of scalp cooling
16.02 – Encouraging patients to research scalp cooling before their treatment
18.04 – The difference between patient and doctor efficacy
21.10 – Patients’ reasons for wanting to scalp cool
25.55 – Scalp cooling with anthracyclines
29.47 – The psychosocial impact of scalp cooling
35.51 – Debunking scalp cooling myths
38.45 – What does changing the face of cancer mean to Dr Conleth Murphy & Sue Glavin?
Dr Conleth Murphy, Consultant Oncologist, Bon Secours Hospital in Cork, Ireland Dr. Conleth Murphy (bonsecours.ie)
Sue Glavin, Nurse Manager, Bon Secours Hospital in Cork, Ireland
The uptake, patient satisfaction and efficacy of scalp cooling among patients receiving chemotherapy in an Irish oncology day ward. (2019, Maher et al.) https://www.annalsofoncology.org/article/S0923-7534(19)59968-9/fulltext
Scalp cooling for hair loss prevention in female Japanese breast cancer patients receiving (neo)adjuvant chemotherapy. (2021, Ohsumi et al.) https://scalpcoolingstudies.com/study-library/ohsumi-2020-observational-study/
